THE ROLE OF C-REACTIVE PROTEIN, PROCALCITONIN AND CYTOKINES PREDICTING BACTERIAL INFECTION IN NEW CORONA VIRUS INFECTION.
Ключевые слова:
SARS-CoV-2, pneumonia, C-reactive protein, procalcitonin, cytokines, biomarkers, prognosis.Аннотация
This article highlights the importance of C-reactive protein (CRP) and procalcitonin (PCT), and cytokines in determining the prognosis of SARS-CoV-2-associated pneumonia. The article discusses the methods used to measure these biomarkers and the results of studies that have investigated their use in predicting the severity and outcome of SARS-CoV-2-associated pneumonia. The article concludes with a discussion of the implications of these findings and suggestions for future research.
Библиографические ссылки
Lanzavecchia A. Antigen-specific interaction between T and B cells // Nature. –1985. –Vol. 314, no. 11. –P. 537–539.
Arsenault, C., Gage, A., Kim, M.K. et al. COVID-19 and resilience of healthcare systems in ten countries. Nat Med 28, 1314–1324 (2022).
Oblokulov, A.R., Husenova, Z. Z., & Ergashev, M. M. (2021). Procalcitonin as an indicator of antibacterial therapy in covid-19. Annals of the Romanian Society for Cell Biology, 5220-5224.
Scaglioni V., Soriano E.R. Are super antigens the cause of cytokine storm and viral sepsis in severe COVID-19? Observations and hypothesis // Scand. J. Immunology –2020. –Vol. 92, no. 6. – P. 1–5.
Oblokulov, A. R., Niyozov, G.E. (2020) Clinical and epidemiological characteristics of patients with COVID-19. International Journal of Pharmaceutical Research; 12(4):3749-3752.
Gorbalenya A.E., et al. The species Severe acute res piratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2 // Nat. Microbiol. –2020. –Vol. 5, no. 4. –P. 536–544.
Oblokulov A.R., Musaeva D.M., Elmuradova A.A. (2020) Clinical and epidemiological characteristics of the new coronavirus infection (COVID-19). // New Day in Medicine. №2 (30/2) p.110-115.
Encyclopaedia Britannica, Inc. – URL: https://www.britannica.com (date of viewing: 12.01.2021).
Mahendra M, Nuchin A, Kumar R, et al. (2021) Predictors of mortality in patients with severe COVID-19 pneumonia—a retrospective study. Adv Respir Med 89:135–144.
Bosch B.J., et al. The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex // J. Virol. –2003. –Vol. 77, no. 16. –P. 8801–8811.
Lanzavecchia A. Antigen-specific interaction between T and B cells // Nature. – 1985. – Vol. 314, no. 11. – P. 537–539.
Westblade LF, Simon MS, Satlin MJ (2021) Bacterial coinfections in coronavirus disease 2019. Trends Microbiol 29:930–941.
Lopez L.A., et al. Importance of conserved cysteine residues in the coronavirus envelope protein // J. Virol. –2008. –Vol. 82, no. 6. –P. 3000–3010. 7.Schoeman, D. Coronavirus envelope protein: current knowledge // Virol. J. –2019. –Vol. 16, no. 1. –P. 69.
Scaglioni V., Soriano E.R. Are superantigens the cause of cytokine storm and viral sepsis in severe COVID-19? Observations and hypothesis // Scand. J. Immunol. – 2020. – Vol. 92, no. 6. – P. 1–5.
Gorbalenya A.E., et al. The species Severe acute res piratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2 // Nat. Microbiol. – 2020. – Vol. 5, no. 4. – P. 536–544.
Encyclopaedia Britannica, Inc. – URL: https:// www.britannica.com (date of viewing: 12.01.2021).
Langford BJ, So M, Simeonova M, et al. (2023) Antimicrobial resistance in patients with COVID-19: a systematic review and meta-analysis. Lancet Microbe 4: e179–e191.
Lopez L.A., et al. Importance of conserved cysteine residues in the coronavirus envelope protein // J. Virol. – 2008. – Vol. 82, no. 6. – P. 3000–3010.
Schoeman, D. Coronavirus envelope protein: current knowledge // Virol. J. – 2019. – Vol. 16, no. 1. – P. 69.
Williams EJ et al. (2020). Routine measurement of serum procalcitonin allows antibiotics to be safely with held in patients admitted to hospital with SARS-CoV-2 infection. medRxiv. doi. org/10.1101/2020.06.29.20136572.
Escher R, Breakey N, Lammle B. Severe COVID-19 infection associated with endothelial activation. Thromb Res.2020; 190:62. doi: 10.1016/j.thromres.2020.04.014.
Hermans C, Lambert C. Impact of the COVID-19 pandemic on therapeutic choices in thrombosis-hemostasis. J Thromb Haemost. 2020 doi: 10.1111/jth.14845.
Ergashov M.M. (2023) The importance of C-reactive protein, Procalcitonin, and cytokines in determining the prospect of SARS-COV-2-associated pnumonia // Horizon Journal of Humanity and Artificial Intelligence. Volume: 02 Issue: 06 | 2023, ISSN: 2835-3064. P. -167-171.
Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020; 395:1033–1034. doi: 10.1016/S0140-6736(20)30628-0.
Nahum J, et al. Venous thrombosis among critically ill patients with coronavirus disease 2019 (COVID-19) JAMA Netw. Open. 2020;3: e2010478. doi: 10.1001/jamanetworkopen.2020.10478.
Niyazov G.E., Oblokulov A.R., Pondina A.I. et al. (2020) Clinical and epidemiological characteristics of COVID-19 patients // New Day in Medicine. №4 (32). P. -110-115.
Cui S, Chen S, Li X, Liu S, Wang F. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J. Thromb. Haemost. 2020; 18:1421–1424. doi: 10.1111/jth.14830.
Niyozov G.E., Mukhtarova Sh.A., Ergashov M.M. (2022) Covid-associated coagulopathy in patients with the new coronavirus infections // Journal infectology. Appendix 1, Volume 14, No. 4, 2022. P. – 73-74.
Zhou F, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020; 395:1054–1062. doi: 10.1016/S0140-6736(20)30566-3.
Guan WJ, et al. Clinical characteristics of coronavirus disease 2019 in China. N. Engl. J. Med. 2020; 382:1708–1720. doi: 10.1056/NEJMoa2002032.
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–1062. doi: 10.1016/S0140-6736(20)30566-3.
Эргашов М.М. (2021). Ролъ прокальцитонинового теста в диагностике и лечении COVID – 19 // III Международное книжное издание – Лучший молодой ученый. Ст.40-42.
Облокулов А.Р., Хусенова З.З., Эргашов М.М. (2021) Значение Уровня Прокальцитонина при назначении и мониторинга антибактериальной терапии пациентов с COVID – 19 // Журнал гепато – гастроэнтерологических исследований. Том №1, Специалый выпуск. Cт. -115-117
Хусенова З.З., Облокулов А.Р. Эргашов М.М. (2021) Клинико – эпидемиологическая характеристика пациентов с SARS CоV – 2 инфекцией // Tibbiyotda yangi kun, №2(34/3)202. Cт. – 270-273.
Wesley H. Self and others, Procalcitonin as a Marker of Etiology in Adults Hospitalized with Community-Acquired Pneumonia, Clinical Infectious Diseases, Volume 65, Issue 2, 15 July 2017, Pages 183–190.
Clyne B, Olshaker JS (1999) The C-reactive protein. J Emerg Med 17:1019–1025.
Xiaomin Luo and others, Prognostic Value of C-Reactive Protein in Patients with Coronavirus 2019, Clinical Infectious Diseases, Volume 71, Issue 16, 15 October 2020, Pages 2174–2179.
Williams EJ et al. (2020) Routine measurement of serum procalcitonin allows antibiotics to be safely with held in patients admitted to hospital with SARS-CoV-2 infection. medRxiv. doi. org/10.1101/2020.06.29.20136572.
Облокулов А.Р., Нарзиев И.И., Облоқулов А.А., Эргашов М.М., Бадиева Б.М. (2021) Пандемия шароитида фаолят кўрсатган тиббиёт ходимларида юзага келаган рухий ўзгаришлар // “Инфекция, имунология, фармакалогия” научно-практический журнал. №1/2021. Cт. -58-62.
Oblokulov A.R., Kholov U.A., Niyozov G.E., Khusenova Z.Z., Ergashov M.M. (2021) Extrapulmonal manifestations of COVID – 19 // “Infection, immunity and pharmacology –scientific and practical journal - №1/2021. P. - 62-66.
Oblokulov A.R., Oblokulov А.А., Ergashov M.M. (2021) Clinical And Laboratory Criteria for spontaneous Bacterial Peritonitis In Liver Cirrhosis Of Viral Etiology // Central asian journal of medical and natural sciences. P. - 172-177.
Облокулов А.Р., Хусенова З.З., Эргашов М.М. (2021) Значимость уровня прокальцитонина при терапии пациентов с COVID – 19 // ВЕСТНИК ТМА Ташкетской медициской академии, Ст. - 42-43.
Эргашов М.М. (2023) SARS-COV-2 bilan bog’liq pnevmoniya istiqbolini belgilashda C-reaktiv oqsil, prokalsitonin va sitokinlarning ahamiyati // НАУЧНЫЙ ИМПУЛЬС Международный современный научно-практический журнал. Новости образования: Исследование в XXI веке № 10(100), часть 1 мая, ст. - 366-369.
Ergashov M.M. (2023) The importance of C-reactive protein, procalcitonin, and cytokines in determining the prospect of SARS-COV-2-associated pneumonia // Galaxy International Interdisciplinary Research Journal (GIIRJ) ISSN (E): 2347-6915. Vol. 11, Issue 04, April. P.-480-483.
Авдеева М.Г., Облокулов А.Р., Эргашов М.М. (2022) Прокальцитонин как предиктор антибактериальной терапии при Covid-19 // Новый День в Медицине Том 2 (40) 2022. Ст. -323-327.
Облокулов А.Р., Хусенова З.З., Эргашов М.М. (2021) Значимость уровня прокальцитонина при терапии пациентов с COVID – 19 // Новый день в медицина 2(34)3. Ст. 267-270.
Rothe K, Feihl S, Schneider J, et al. (2021) Rates of bacterial co-infections and antimicrobial use in COVID-19 patients: a retrospective cohort study in light of antibiotic stewardship. Eur J Clin Microbiol Infect Dis 40:859–869
Эргашов М.М., Бомомуратова М.Н. (2023) Прокальцитонин – перспективный диагностический маркер для управления антибактериальными терапии при COVID-19 // Лучшие интеллектуальные исследования. Часть-6, Том-1, ст. -89-94.
Эргашов М.М. (2023) Прогностическое значение прокальцитонинина при COVID – 19 // Ta'lim innovatsiyasi va integratsiyasi. 11-son, 3-to’plam, cт. -122-128.
Эргашов М.М. (2023) Биомаркер прокальцитонин как прогностический фактор антибактериальной терапии covid-19 // “O‘zbekistonda fanlararo innovatsiyalar va ilmiy tadqiqotlar” jurnali. ст. - 30-37.
